drugset / Trial / NCT00115414

Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC)

NCT00115414 ↗

Phase 2 Completed Amgen
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to provide data on the safety and efficacy of pegfilgrastim when administered on the same day versus the next day of chemotherapy, as measured by the duration of grade 4 neutropenia.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegfilgrastim Protein / enzyme biologic — —
Background Cyclophosphamide Other / unclassified — —
Background Docetaxel Small molecule — —
Background Doxorubicin Other / unclassified — —